Anxiety and depression symptoms after virological clearance of COVID‐19: A cross‐sectional study in Milan, Italy

Prevalence of anxiety or depression was investigated in 105 coronavirus disease 2019 (COVID‐19) patients at 1 to 3 months from virological clearance by hospital anxiety and depression scale (HADS‐A/D). 30% of patients displayed pathological HADS‐A/D, 52.4% showed persistent symptoms. Pathological pa...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of medical virology Ročník 93; číslo 2; s. 1175 - 1179
Hlavní autoři: Tomasoni, Daniele, Bai, Francesca, Castoldi, Roberto, Barbanotti, Diletta, Falcinella, Camilla, Mulè, Giovanni, Mondatore, Debora, Tavelli, Alessandro, Vegni, Elena, Marchetti, Giulia, d'Arminio Monforte, Antonella
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Wiley Subscription Services, Inc 01.02.2021
John Wiley and Sons Inc
Témata:
Adult
Aged
Anxiety
Anxiety - epidemiology
anxiety and depression symptoms
Coronaviruses
COVID-19
COVID-19 - complications
COVID-19 - epidemiology
COVID-19 - psychology
Cross-Sectional Studies
Depression - epidemiology
Female
hospital anxiety and depression scale
Humans
Italy - epidemiology
Male
Mental depression
Middle Aged
Patients
Prevalence
Psychological assessment
Short Communication
Short Communications
Signs and symptoms
Surveys and Questionnaires
Viral diseases
Virology
Italy
Milan Italy
COVID-19
anxiety and depression symptoms
hospital anxiety and depression scale
ISSN:0146-6615, 1096-9071, 1096-9071
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Prevalence of anxiety or depression was investigated in 105 coronavirus disease 2019 (COVID‐19) patients at 1 to 3 months from virological clearance by hospital anxiety and depression scale (HADS‐A/D). 30% of patients displayed pathological HADS‐A/D, 52.4% showed persistent symptoms. Pathological patients with HADS‐A/D more commonly reported symptom persistence, even after adjustment for age, gender, and disease severity. Psychological assessments should be encouraged in COVID‐19 patients' follow‐up. Highlights 1‐3 months after clinical and virological recovery from symptomatic COVID‐19 disease, 30% and 52.4% of patients still presented psychological and physical symptoms, respectively Persistence of anxiety and depression was independently associated with ongoing physical symptoms Psychological evaluations should be included in the follow‐up of COVID‐19 patients.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0146-6615
1096-9071
1096-9071
DOI:10.1002/jmv.26459